TEPMETKO demonstrated a manageable safety profile that maintained quality of life*^1–4

Common AEs

Most common AEs were mild to moderate²

Few discontinuations: only 14.7% of TrAEs led to discontinuation¹
TrAEs occurred in 91.7% of patients with a low rate of grade ≥3 (34.8%) and grade ≥4 (3.8%) TrAEs¹
TrAEs occurring in >20% of patients: peripheral edema (67.1%), hypoalbuminemia (23.6%), nausea (23.3%), diarrhea (22.4%) and increased blood creatinine (22.0%)¹
Favorable gastrointestinal tolerability: low rates of all-grade nausea (31%), diarrhea (29%) and vomiting (14%)⁵
When required, AEs were effectively managed by simple dose modifications⁵
33.5% of patients experienced dose reduction and 43.1% treatment interruption¹

TrAEs occurring in ≥10% of patients²

SYSTEM ORGAN CLASS/AR	OVERALL (N=313), %
SYSTEM ORGAN CLASS/AR	ALL GRADES	GRADE ≥3
Metabolism and nutrition disorders
Hypoalbuminemia	23.6	3.5
Gastrointestinal disorders
Nausea	23.3	0.6
Diarrhea	22.4	0.3
Decreased appetite	11.2	0.3
Hepatobiliary, renal and urinary disorders
Increase in ALT	14.1	2.2
Increase in blood creatinine	22.0	1.0
General disorders
Peripheral edema	67.1	11.2

Adapted from Mazieres et al. 2023²

Quality of life

Quality of life was maintained throughout treatment³

Change in HRQoL scores from baseline^**3

Adapted from Paik et al. 2023³

Maintenance of QoL

As demonstrated by global functioning scores³

Adapted from Paik et al. 2023³

Dosing

Choose simplicity: TEPMETKO is the only MET inhibitor with once-daily oral dosing^††5

Patient satisfaction

Limit the tablet burden with a once-daily oral dosing regimen, proven to improve patient satisfaction, adherence and quality of life⁵

Dosing

450 mg daily dose of 2 x 225 mg tablets^‡5

Dose modification

If your patient requires an easy dose modification due to AEs, TEPMETKO is the only MET inhibitor that offers a prescription-free drop from two tablets to one^‡‡5

Symptom reduction and stabilisation

Patients experienced a reduction in cough and stability in dyspnea and pain symptoms^†3

Recommended dose modifications

If your patient requires an easy dose modification due to AEs, TEPMETKO is the only MET inhibitor that offers a prescription-free drop from two tablets to one⁵

Dose modification table

ADVERSE REACTION	SEVERITY	DOSE MODIFICATION
Interstitial lung disease (ILD)	Any grade	Withhold TEPMETKO if ILD is suspected. Permanently discontinue TEPMETKO if ILD is confirmed
Increased ALT and/or AST without increased total bilirubin	Grade 3	Withhold TEPMETKO until recovery to baseline ALT/AST. If recovered to baseline within 7 days, then resume TEPMETKO at the same dose; otherwise resume TEPMETKO at a reduced dose
Increased ALT and/or AST without increased total bilirubin	Grade 4	Permanently discontinue TEPMETKO
Increased ALT and/or AST with increased total bilirubin in the absence of cholestasis or hemolysis	ALT and/or AST greater than 3 times ULN with total bilirubin greater than 2 times ULN	Permanently discontinue TEPMETKO
Increased total bilirubin without concurrent increased ALT and/or AST	Grade 3	Withhold TEPMETKO until recovery to baseline bilirubin. If recovered to baseline within 7 days, then resume TEPMETKO at a reduced dose; otherwise permanently discontinue
	Grade 4	Permanently discontinue TEPMETKO
Other adverse reactions	Grade 2	Maintain dose level. If intolerable, consider withholding TEPMETKO until resolved, then resume TEPMETKO at a reduced dose
	Grade 3	Withhold TEPMETKO until resolved, then resume TEPMETKO at a reduced dose
	Grade 4	Permanently discontinue TEPMETKO

Identify and manage AEs early on to maximize treatment benefits and minimize impact on patients’ QoL^4,6

Managing peripheral edema

Peripheral edema is a class effect – identifying and managing it early on helps to maximize treatment benefit^6,7

Amongst the 313 patients involved in the VISION study, peripheral edema was mostly mild to moderate; 11.2% of patients experienced a grade 3 event and none experienced a grade 4 event.^1,6

Most patients with peripheral edema can continue treatment with TEPMETKO as reflected by the low rate (4.3%) of permanent treatment discontinuation in the VISION study^4,6

Manage peripheral edema with a multimodal approach to help patients stay on TEPMETKO for as long as needed^4,6,8

Effective management of peripheral edema includes:

Prevention
Intervention

Incorporating preventative measures at the start of therapy can help patients derive maximum benefit from TEPMETKO^1,6

Regular monitoring

Check body weight and limb size, and perform visual checks for swelling and skin changes⁶

Lifestyle changes

Encourage physical activity to help manage edema before it becomes hard to treat⁶

Physical changes

Limb elevation and compression stockings help to reduce edema^6,8

Help patients stay on TEPMETKO for as long as possible with individualized AE management strategies^6,8,9

Diuretics

Increase fluid excretion via urine⁶

Complementary therapies

Improve blood flow and reduce swelling with lymphatic massage and kinesiotherapy^6,8,10

Dose reduction

Apply when necessary and restart once edema improves to grade ≤2^5,6,10

Tailored communication can empower patients to make informed choices, help mitigate the impact of AEs on their QoL and improve treatment adherence⁶

With TEPMETKO, give your patients more moments that matter

3–4% of your patients with NSCLC may have METex14 skipping^9,11,12

Explore the importance of timely targeted therapy for your NSCLC patients

Learn more about the unmet need

Explore the VISION trial

Learn more about the patient characteristics, efficacy outcomes and design of VISION, a single-arm, open-label, multicenter, non-randomized, multi-cohort study that analyzed patients with METex14 skipping NSCLC (N=313)^1,9

Learn more about VISION trial

TEPMETKO may offer substantially increased mDOR vs. capmatinib¹³

A matching-adjusted indirect comparison (MAIC) of TEPMETKO vs. capmatinib has shown improved mDOR, mOS and mPFS¹³

Learn more about MAIC outcomes

*Cohort A follow-up >35 months; Cohort C follow-up >18 months; median follow-up of Cohorts A+C 32.6 months¹
**An increase or decrease of >10 points was considered to be clinically meaningful. All scores graded out of 100, with higher=better³
^†Measured by EORTC QLQ-C30 GHS³
^††In China, TEPMETKO is not the only MET inhibitor with once-daily dosing^‡See PI for recommended dose modifications^{5

‡‡}TEPMETKO is administered as 450 mg tepotinib (2 × 225 mg tablets); equivalent to 500 mg tepotinib hydrochloride hydrate (2 × 250 mg tablets)^5,14

Abbreviations

AE, adverse event; ALT, alanine aminotransferase; AR, adverse reaction; AST, aspartate aminotransferase; EORTC QLQ-C30 GHS, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 global health score; HRQoL; health-related quality of life; ILD, interstitial lung disease; MAIC, matching-adjusted indirect comparison; MET, mesenchymal epithelial transition factor; METex14, mesenchymal epithelial transition factor exon 14; mDOR, median duration of response; mOS, median overall survival; mPFS, median progression-free survival; NSCLC, non-small cell lung cancer; QoL, quality of life; TrAE; treatment-related adverse event; ULN, upper limit of normal

Reference

Mazieres J et al. JAMA Oncol 2023; 9:1260−1266.
Mazieres J et al. JAMA Oncol 2023; 9:1260–1266 (supplementary appendix 2).
Paik PK et al. Presented virtually at: American Society of Clinical Oncology (ASCO) Annual Meeting 2023; 2–6 June 2023; Chicago, IL, USA (Abstract no. 9060).
Veillon R et al. Clin Lung Cancer 2022; 23:320–332.
TEPMETKO® (tepotinib) [prescribing information], EMD Serono, Inc., Rockland, MA; 2024.
Ahn L et al. Clin J Oncol Nurs 2022; 26:543–551.
Cortot A et al. Clin Lung Cancer 2022; 23:195−207.
Ferrara R et al. Presented at: European Lung Cancer Congress (ELCC) 2023; 29 March−1 April 2023; Copenhagen, Denmark (Poster no. 33P).
Paik PK et al. N Engl J Med 2020; 383:931–943.
Nishio M et al. Targeted Oncol 2022; 17:597−604.
Salgia R. Mol Cancer Ther 2017; 16:555–565.
Tong JH et al. Clin Cancer Res 2016; 22:3048–3056.
Pfeiffer BM et al. Presented at: IASLC World Conference on Lung Cancer (WCLC) 2023; 9−12 September 2023; Virtually and Singapore (Poster no. 1312).
Paik PK et al. N Engl J Med 2020; 383:931–943 (supplementary appendix).

This website is an international information resource intended only for healthcare professionals from outside the European Economic Area (EEA), the US, Puerto Rico and Canada who are interested in information on TEPMETKO. The information on this website contains educational and promotional material. By clicking on 'I'm a healthcare professional' you are declaring and confirming that are you a healthcare professional and have read and understood this.

GL-TEP-00506 | April 2025

This website is an international information resource intended only for Healthcare Professionals from outside the European Economic Area (EEA), the US, Puerto Rico
and Canada who are interested in information on TEPMETKO.

TEPMETKO demonstrated a manageable safety profile that maintained quality of life*1–4

Common AEs

TrAEs occurring in ≥10% of patients2

Quality of life

Quality of life was maintained throughout treatment3

Maintenance of QoL

Dosing

Patient satisfaction

Dosing

Dose modification

Symptom reduction and stabilisation

Recommended dose modifications

Dose modification table

Managing peripheral edema

Peripheral edema is a class effect – identifying and managing it early on helps to maximize treatment benefit6,7

Manage peripheral edema with a multimodal approach to help patients stay on TEPMETKO for as long as needed4,6,8

Incorporating preventative measures at the start of therapy can help patients derive maximum benefit from TEPMETKO1,6

Regular monitoring

Lifestyle changes

Physical changes

Help patients stay on TEPMETKO for as long as possible with individualized AE management strategies6,8,9

Diuretics

Complementary therapies

Dose reduction

With TEPMETKO, give your patients more moments that matter

3–4% of your patients with NSCLC may have METex14 skipping9,11,12

Explore the VISION trial

TEPMETKO may offer substantially increased mDOR vs. capmatinib13

Abbreviations

Reference

Prescribing Information

Cookie Disclamer

TEPMETKO demonstrated a manageable safety profile that maintained quality of life*^1–4

TrAEs occurring in ≥10% of patients²

Quality of life was maintained throughout treatment³

Peripheral edema is a class effect – identifying and managing it early on helps to maximize treatment benefit^6,7

Manage peripheral edema with a multimodal approach to help patients stay on TEPMETKO for as long as needed^4,6,8

Incorporating preventative measures at the start of therapy can help patients derive maximum benefit from TEPMETKO^1,6

Help patients stay on TEPMETKO for as long as possible with individualized AE management strategies^6,8,9

3–4% of your patients with NSCLC may have METex14 skipping^9,11,12

TEPMETKO may offer substantially increased mDOR vs. capmatinib¹³